Cannabidiol-Loaded Retinal Organoid-Derived Extracellular Vesicles Protect Oxidatively Stressed ARPE-19 Cells
<b>Background/Objectives:</b> Age-related macular degeneration (AMD) is the third leading cause of irreversible blindness in elderly individuals aged over 50 years old. Oxidative stress plays a crucial role in the etiopathogenesis of multifactorial AMD disease. The phospholipid bilayer EVs derived from the culture-conditioned medium of human induced pluripotent stem cell (hiPSC) differentiated retinal organoids aid in cell-to-cell communication, signaling, and extracellular matrix remodeling. The goal of the current study is to establish and evaluate the encapsulation of a hydrophobic compound, cannabidiol (CBD), into retinal organoid-derived extracellular vesicles (EVs) for potential therapeutic use in AMD. <b>Methods:</b> hiPSC-derived retinal organoid EVs were encapsulated with CBD via sonication (CBD-EVs), and structural features were elucidated using atomic force microscopy, nanoparticle tracking analysis, and small/microRNA (miRNA) sequencing. ARPE-19 cells and oxidative-stressed (H<sub>2</sub>O<sub>2</sub>) ARPE-19 cells treated with CBD-EVs were assessed for cytotoxicity, apoptosis (MTT assay), reactive oxygen species (DCFDA), and antioxidant proteins (immunohistochemistry and Western blot). <b>Results:</b> Distinct miRNA cargo were identified in early and late retinal organoid-derived EVs, implicating their roles in retinal development, differentiation, and functionality. The therapeutic effects of CBD-loaded EVs on oxidative-stressed ARPE-19 cells showed greater viability, decreased ROS production, downregulated expression of inflammation- and apoptosis-related proteins, and upregulated expression of antioxidants by Western blot and immunocytochemistry. <b>Conclusions:</b> miRNAs are both prognostic and predictive biomarkers and can be a target for developing therapy since they regulate RPE physiology and diseases. Our findings indicate that CBD-EVs could potentially alleviate the course of AMD by activating the targeted proteins linked to the adenosine monophosphate kinase (AMPK) pathway. Implicating the use of CBD-EVs represents a novel frontline to promote long-term abstinence from drugs and pharmacotherapy development in treating AMD.
Authors
- Anil Kumar Kalvala (ORCID: https://orcid.org/0000-0003-4500-1472)
- Aakash Nathani (ORCID: https://orcid.org/0000-0003-1852-6548)
- Sangeetha Kandoi (ORCID: https://orcid.org/0000-0001-8346-8642)
- Mandip Singh Sachdeva (ORCID: https://orcid.org/0000-0001-9192-8143)
- Peggy Arthur (ORCID: https://orcid.org/0000-0002-6225-2639)
- Li Sun (ORCID: https://orcid.org/0000-0001-8228-7487)
- Deepak A. Lamba (ORCID: https://orcid.org/0000-0002-2811-307X)
- Tanmay Kulkarni (ORCID: https://orcid.org/0000-0002-9194-2460)
- Mounika Aare (ORCID: https://orcid.org/0000-0001-7809-4682)
- Breana Boirie
- Yan Li (ORCID: https://orcid.org/0000-0002-5938-8519)
- Santanu Bhattacharya (ORCID: https://orcid.org/0000-0003-3579-4317)
Institutions
- Florida State University (US)
- Florida A&M University - Florida State University College of Engineering (US)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- California Institute for Regenerative Medicine (US)
- Jacksonville College (US)
- Broad Center (US)
- Florida Agricultural and Mechanical University (US)
Publication Details
- Journal
- Biomedicines
- Published
- 2025-05-10
- DOI
- https://doi.org/10.3390/biomedicines13051167
- Citations
- 3
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Knights Templar Eye Foundation
- National Institutes of Health
- National Institute on Minority Health and Health Disparities